BR112013013684A2 - tratamento das condiçóes mediadas por jak-2 - Google Patents
tratamento das condiçóes mediadas por jak-2Info
- Publication number
- BR112013013684A2 BR112013013684A2 BR112013013684A BR112013013684A BR112013013684A2 BR 112013013684 A2 BR112013013684 A2 BR 112013013684A2 BR 112013013684 A BR112013013684 A BR 112013013684A BR 112013013684 A BR112013013684 A BR 112013013684A BR 112013013684 A2 BR112013013684 A2 BR 112013013684A2
- Authority
- BR
- Brazil
- Prior art keywords
- jak
- treatment
- mediated conditions
- mediated
- conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41947610P | 2010-12-03 | 2010-12-03 | |
US201161492485P | 2011-06-02 | 2011-06-02 | |
PCT/AU2011/001551 WO2012071612A1 (en) | 2010-12-03 | 2011-11-29 | Treatment of jak2-mediated conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013013684A2 true BR112013013684A2 (pt) | 2016-09-06 |
Family
ID=46171087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013013684A BR112013013684A2 (pt) | 2010-12-03 | 2011-11-29 | tratamento das condiçóes mediadas por jak-2 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20140073643A1 (pt) |
EP (1) | EP2646029A4 (pt) |
JP (2) | JP2013544260A (pt) |
KR (1) | KR20130137011A (pt) |
CN (2) | CN103370068A (pt) |
AU (1) | AU2011335882B2 (pt) |
BR (1) | BR112013013684A2 (pt) |
CA (1) | CA2819560A1 (pt) |
EA (1) | EA201390815A1 (pt) |
MX (1) | MX2013006261A (pt) |
NZ (1) | NZ611654A (pt) |
SG (2) | SG10201509919UA (pt) |
WO (1) | WO2012071612A1 (pt) |
ZA (1) | ZA201304280B (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
HUE046493T2 (hu) | 2009-05-22 | 2020-03-30 | Incyte Holdings Corp | 3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként |
MY175156A (en) | 2010-03-10 | 2020-06-11 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
TWI499421B (zh) | 2010-05-21 | 2015-09-11 | Incyte Corp | Jak抑制劑的局部製劑 |
CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
US20150299796A1 (en) * | 2012-07-27 | 2015-10-22 | Alexander CAO | Prediction of treatment response to jak/stat inhibitor |
WO2014078486A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
ES2707355T3 (es) | 2013-03-06 | 2019-04-03 | Incyte Holdings Corp | Procesos y productos intermedios para elaborar un inhibidor de JAK |
EP2981252A4 (en) * | 2013-04-04 | 2017-02-22 | Olivia Newton-John Cancer Research Institute | Methods of treating diseases characterized by excessive wnt signalling |
CA3155500A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
PE20161388A1 (es) * | 2014-02-28 | 2016-12-28 | Incyte Corp | Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
TWI681954B (zh) * | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
LT3179992T (lt) | 2014-08-11 | 2022-06-27 | Acerta Pharma B.V. | Btk inhibitoriaus, pd-1 inhibitoriaus ir (arba) pd-l1 inhibitoriaus terapiniai deriniai |
HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
US20170224819A1 (en) | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
CN106316964B (zh) | 2015-06-26 | 2019-06-25 | 苏州泽璟生物制药股份有限公司 | 苯基氨基嘧啶化合物或其盐的多晶型物 |
CN106316963B (zh) * | 2015-06-26 | 2021-06-08 | 苏州泽璟生物制药股份有限公司 | ***啉苯基氨基嘧啶化合物或其盐的多晶型物 |
WO2018031579A1 (en) | 2016-08-10 | 2018-02-15 | Gilead Sciences, Inc. | Momelotinib for treating of acvr1 -mediated diseases |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
MA51771B1 (fr) | 2018-01-30 | 2022-03-31 | Incyte Corp | Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) |
CN109045040A (zh) * | 2018-03-12 | 2018-12-21 | 首都医科大学附属北京天坛医院 | Cyt387用于制备治疗神经胶质瘤的药物的应用 |
PE20210402A1 (es) | 2018-03-30 | 2021-03-02 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak |
EP3840752A4 (en) * | 2018-08-21 | 2022-05-18 | Sierra Oncology, Inc. | PLATELET COUNT AGNOSTIC METHODS FOR TREATMENT OF MYELOFIBROSIS |
US20200323851A1 (en) * | 2019-01-10 | 2020-10-15 | Tolero Pharmaceuticals, Inc. | Alk5 inhibitors for treating myelodysplastic syndrome |
CA3166545A1 (en) * | 2020-01-29 | 2021-08-05 | Igor THEURL | Methods of using momelotinib to treat joint inflammation |
CN111358791A (zh) * | 2020-03-13 | 2020-07-03 | 深圳百奥捷生物科技有限公司 | Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101566840B1 (ko) * | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
US20100310563A1 (en) * | 2007-11-30 | 2010-12-09 | Bumm Thomas G P | Methods for treating induced cellular proliferative disorders |
CA2732791A1 (en) * | 2008-08-05 | 2010-02-11 | Targegen, Inc. | Methods of treating thalassemia |
-
2011
- 2011-11-29 NZ NZ611654A patent/NZ611654A/en unknown
- 2011-11-29 CN CN2011800639895A patent/CN103370068A/zh active Pending
- 2011-11-29 AU AU2011335882A patent/AU2011335882B2/en active Active
- 2011-11-29 CA CA2819560A patent/CA2819560A1/en not_active Abandoned
- 2011-11-29 EA EA201390815A patent/EA201390815A1/ru unknown
- 2011-11-29 KR KR1020137017256A patent/KR20130137011A/ko not_active Application Discontinuation
- 2011-11-29 SG SG10201509919UA patent/SG10201509919UA/en unknown
- 2011-11-29 SG SG2013042239A patent/SG190950A1/en unknown
- 2011-11-29 WO PCT/AU2011/001551 patent/WO2012071612A1/en active Application Filing
- 2011-11-29 CN CN201410578333.2A patent/CN104473933A/zh active Pending
- 2011-11-29 BR BR112013013684A patent/BR112013013684A2/pt not_active IP Right Cessation
- 2011-11-29 US US13/991,139 patent/US20140073643A1/en not_active Abandoned
- 2011-11-29 MX MX2013006261A patent/MX2013006261A/es not_active Application Discontinuation
- 2011-11-29 JP JP2013541149A patent/JP2013544260A/ja active Pending
- 2011-11-29 EP EP11845391.9A patent/EP2646029A4/en not_active Withdrawn
-
2013
- 2013-06-11 ZA ZA2013/04280A patent/ZA201304280B/en unknown
-
2015
- 2015-08-13 JP JP2015159834A patent/JP2015212305A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20140073643A1 (en) | 2014-03-13 |
CN103370068A (zh) | 2013-10-23 |
AU2011335882B2 (en) | 2016-03-10 |
MX2013006261A (es) | 2013-10-01 |
WO2012071612A1 (en) | 2012-06-07 |
EP2646029A1 (en) | 2013-10-09 |
ZA201304280B (en) | 2014-08-27 |
NZ611654A (en) | 2015-08-28 |
AU2011335882A1 (en) | 2013-05-02 |
SG10201509919UA (en) | 2016-01-28 |
EP2646029A4 (en) | 2014-06-18 |
CA2819560A1 (en) | 2012-06-07 |
JP2013544260A (ja) | 2013-12-12 |
SG190950A1 (en) | 2013-07-31 |
KR20130137011A (ko) | 2013-12-13 |
EA201390815A1 (ru) | 2013-12-30 |
JP2015212305A (ja) | 2015-11-26 |
CN104473933A (zh) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013013684A2 (pt) | tratamento das condiçóes mediadas por jak-2 | |
BR112013010007A2 (pt) | aparelho de cateter | |
CO6930321A2 (es) | Curación de tejidos | |
IL220876A0 (en) | Treatment of cardiac conditions | |
DK2863990T3 (da) | Medicinsk mikroelektrode | |
DK2646647T3 (da) | Frakturkarakterisering | |
DK3124610T3 (da) | Hbv-behandling | |
BR112013030398A2 (pt) | cateter de ablação com balão | |
BR112012002571A2 (pt) | tratamento de minérios de titânio | |
HK1198812A1 (en) | Treatment of rhinitis | |
BR112013011659A2 (pt) | métodos de tratamento do câncer | |
IL256026A (en) | Treatment methods | |
DE112011103919A5 (de) | Endoskop | |
BR112014004434A2 (pt) | cateter biocompatível | |
DK2453858T3 (da) | Fremgangsmåde | |
IL225896A0 (en) | Treatment of mecp-2 related disorders | |
BRPI1007543A2 (pt) | tratamento de psoríase | |
DK2501381T3 (da) | Behandling af atrieflimmer | |
DK2590565T3 (da) | Blodprøvetagning | |
FI20106078A0 (fi) | Puukuitupitoisen jakeen käsittely | |
IT1392635B1 (it) | Trattamento ematico di ozonoterapia | |
DK2694056T3 (da) | Terapeutisk behandling | |
IL231143A0 (en) | Treatment of rhinitis | |
PL395785A1 (pl) | Zastosowanie medyczne N-etylo-3-amino-4-fenylo-5-okso-2,5-dihydro-1H-pirazolo-1-karbotioamidu | |
DK2456445T3 (da) | Middel til behandling af hudlidelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2542 DE 24-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |